The association between CD2+ peripheral blood lymphocyte subsets and the relapse of bladder cancer in prophylactically BCG-treated patients.
We investigated the potential existence of differences in the distribution of T-lymphocyte subsets and in the proliferative response of these CD2+ cells to polyclonal mitogens in patients with transitional cell bladder carcinoma (SBTCC) treated with prophylactic intracavitary instillations of bacillus Calmette-Guerin (BCG) according to their clinical response to this treatment. Before BCG treatment, different subset distribution (CD8+ and CD3+ CD56+), activation antigen expression (CD3+ HLA- DR+) and proliferative response to mitogenic signals were found in CD2+ cells from SBTCC patients prophylactically treated with BCG who remained free of disease or those who had recurrence of tumour. Otherwise, the prophylactic intracavitary BCG instillations in SBTCC patients are associated with a transitory variation of T-lymphocyte subset distribution (CD4 and CD8) and activation antigens expression (CD25).
Reyes
E
E
Department of Medicine, University Hospital Principe de Asturias, University of Alcalá, Madrid, Spain.
Carballido
J
J
Manzano
L
L
Moltó
L
L
Olivier
C
C
Alvarez-Mon
M
M
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001500:BCG Vaccine / Q000627:therapeutic use*; D018801:CD2 Antigens / Q000378:metabolism*; D016516:CD4-CD8 Ratio; D006801:Humans; D008213:Lymphocyte Activation; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D016176:T-Lymphocyte Subsets / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000517:prevention & control
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D018801:CD2 Antigens